Literature DB >> 9311747

Analysis of genetic linkage and somatic loss of heterozygosity in affected pairs of first-degree relatives.

K Rohde1, M D Teare, M Santibáñez Koref.   

Abstract

Recently, data on loss of constitutional heterozygosity (LOH) have been used by several groups to increase the power to detect linkage in pedigrees with an inherited cancer predisposition. This approach assumes that the predisposition is due to the inheritance of the defective copy of a tumor suppressor. In order to assess the gain of power expected from the inclusion of LOH data, we simulated segregation and somatic loss of alleles in pedigrees consisting of an affected pair of first-degree relatives. We explored the effects of pedigree structure, frequency of loss, penetrance, and recombination rate on the expected LOD score. The results indicate that, for establishment of genetic linkage, isolated parent-offspring pairs can be as informative as sib pairs and that they could represent an additional source of information in linkage studies.

Entities:  

Mesh:

Year:  1997        PMID: 9311747      PMCID: PMC1715901          DOI: 10.1086/514849

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  12 in total

1.  A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li-Fraumeni patients carrying a mutation to the TP53 gene.

Authors:  J M Varley; M Thorncroft; G McGown; J Appleby; A M Kelsey; K J Tricker; D G Evans; J M Birch
Journal:  Oncogene       Date:  1997-02-20       Impact factor: 9.867

2.  Faster sequential genetic linkage computations.

Authors:  R W Cottingham; R M Idury; A A Schäffer
Journal:  Am J Hum Genet       Date:  1993-07       Impact factor: 11.025

Review 3.  The use of loss of constitutional heterozygosity data to ascertain the location of predisposing genes in cancer families.

Authors:  M D Teare; K Rohde; M F Santibáñez Koref
Journal:  J Med Genet       Date:  1994-06       Impact factor: 6.318

4.  Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium.

Authors:  D F Easton; D T Bishop; D Ford; G P Crockford
Journal:  Am J Hum Genet       Date:  1993-04       Impact factor: 11.025

5.  Computer-simulation methods in human linkage analysis.

Authors:  J Ott
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

6.  Somatic allele loss in genetic linkage analysis of cancer.

Authors:  T R Rebbeck; E D Lustbader; K H Buetow
Journal:  Genet Epidemiol       Date:  1994       Impact factor: 2.135

7.  Using loss of heterozygosity data in affected pedigree member linkage tests.

Authors:  E d Lustbader; T R Rebbeck; K H Buetow
Journal:  Genet Epidemiol       Date:  1995       Impact factor: 2.135

8.  High allele loss rates at 17q12-q21 in breast and ovarian tumors from BRCAl-linked families. The Breast Cancer Linkage Consortium.

Authors:  R S Cornelis; S L Neuhausen; O Johansson; A Arason; D Kelsell; B A Ponder; P Tonin; U Hamann; A Lindblom; P Lalle
Journal:  Genes Chromosomes Cancer       Date:  1995-07       Impact factor: 5.006

9.  Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13.

Authors:  N Collins; R McManus; R Wooster; J Mangion; S Seal; S R Lakhani; W Ormiston; P A Daly; D Ford; D F Easton
Journal:  Oncogene       Date:  1995-04-20       Impact factor: 9.867

10.  Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer.

Authors:  T Sato; A Tanigami; K Yamakawa; F Akiyama; F Kasumi; G Sakamoto; Y Nakamura
Journal:  Cancer Res       Date:  1990-11-15       Impact factor: 12.701

View more
  1 in total

1.  Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis.

Authors:  T A Smolarek; L L Wessner; F X McCormack; J C Mylet; A G Menon; E P Henske
Journal:  Am J Hum Genet       Date:  1998-04       Impact factor: 11.025

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.